Compare Intel Corp (INTC) vs TG Therapeutics Inc (TGTX) Price & Performance

Intel (INTC) trades at $105.75, down 6.52% over the past 24 hours, with a mixed technical picture showing bullish overall signals but bearish moving averages and oscillators. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.42 beating expectations of $0.21. However, Intel faces fundamental challenges with negative net income margins (-19.79%) and elevated valuation ratios (P/E of 904.17), though operating cash flow improved to $9.7 billion in 2025.

Intel's turnaround story shows early signs of progress with strong foundry revenue growth and government support, but profitability remains a concern. The stock offers potential upside to the analyst consensus price target of $111.72, though execution risks in the competitive semiconductor space and high debt levels pose significant challenges for investors seeking sustained recovery.

TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.

The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.